The UK leaves the European Union at 23:00 (GMT) this evening. Whilst nothing looks set to change dramatically overnight for brain tumour patients, the future is unclear. Both the EU and UK seem committed to maintaining existing levels of cooperation; however, the very limited transition period may not leave much scope for exact arrangements to be confirmed.
It has recently been confirmed that UK researchers will be able to participate in, bid for and lead projects in the European Union’s flagship research programme Horizon 2020, as if the UK remained a Member State, even after the UK exits the EU today. This support from Horizon 2020 will continue for the lifetime of individual projects, including projects finishing after the transition period ends in 2020.
Exactly how Brexit will affect research into brain tumours is a complex topic that is likely to unfold gradually over a relatively long period. You can read some of Brain Tumour Research’s thoughts on this topic below:
- Brexit uncertainty and UK research
- Brain Tumour Research calls upon government to maintain European research collaboration
- The UK leads Europe in early-stage clinical research
If you found this story interesting or helpful, sign up to our weekly e-news and keep up to date with all the latest from Brain Tumour Research.